Catalent issues initial public offering

Catalent Inc. has announced the next step in its growth journey as the global leader and the #1 pharmaceutical industry partner in advanced drug delivery technology and drug development solutions.

As of 31 July 2014, Catalent Inc. has completed an initial public offering and is now a publicly traded company on the New York Stock Exchange. The company's new trading ticker on the big board is CTLT.

"At Catalent we work with more than a thousand pharmaceutical, biotech and consumer health companies to help them develop better products. We are the global leader in advanced drug delivery technologies and drug development solutions. We have more than 8000 great people, including 1000+ scientists and technicians, in nearly 30 manufacturing locations globally, who every day reliably supply more than 7000 products for patients and consumers worldwide," siad John Chiminski, president and CEO of Catalent.